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Insulin resistance associated with type 2 diabetes mellitus (T2DM), obesity, and atherosclerosis is a global health
problem. A portfolio of abnormalities of metabolic and vascular homeostasis accompanies T2DM and obesity,
which are believed to conspire to lead to accelerated atherosclerosis and premature death. The complexity of
metabolic changes in the diseases presents challenges for a full understanding of the molecular pathways
contributing to the development of these diseases. The recent advent of new technologies in this area termed
“Metabolomics” may aid in comprehensive metabolic analysis of these diseases. Therefore, metabolomics has been
extensively applied to the metabolites of T2DM, obesity, and atherosclerosis not only for the assessment of disease
development and prognosis, but also for the biomarker discovery of disease diagnosis. Herein, we summarize the
recent applications of metabolomics technology and the generated datasets in the metabolic profiling of these
diseases, in particular, the applications of these technologies to these diseases at the cellular, animal models, and
human disease levels. In addition, we also extensively discuss the mechanisms linking the metabolic profiling in
insulin resistance, T2DM, obesity, and atherosclerosis, with a particular emphasis on potential roles of increased
production of reactive oxygen species (ROS) and mitochondria dysfunctions.
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The metabolome is the terminal product downstream
from the genome, transcriptome, and proteome, and
consists of the total complement of all the low-molecular
-weight molecules (metabolites) in a cell, tissue, or organ-
ism [1,2]. Metabolomics is well defined as a technology
aiming to measure/profile metabolite changes present
within a cell, tissue, or organism in response to a genetic
alteration or pathophysiological stimuli [3,4]. Downstream
of transcriptional, posttranscriptional, translational, and
posttranslational processes (Figure 1), metabolites serve as
the most proximal reporters of alteration in the body/
tissue/cells in response to a disease process. Measurement
of time-related metabolic changes in animal models in
response to genetic manipulation can be used to define the
varying phenotypes observed [5]. In general, metabolomics* Correspondence: xfyang@temple.edu
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reproduction in any medium, provided the ormethodologies fall into two distinct groups: untargeted
metabolomics, an intended comprehensive analysis of all
the measurable identities in a sample including chemical
unknowns; and targeted metabolomics, the measurement
of defined groups of chemically characterized and biochem-
ically annotated metabolites. The results of targeted
metabolomics studies have demonstrated both feasibility
and flexibility across physiological, pathological, interven-
tional, and epidemiological human studies. In addition to
the identifications of metabolites in the process of disor-
ders, metabolomics also has the groups of well-established
web-based databases available. These databases have linked
the identified metabolites or compounds with specific
disorders and physiological characteristics (Tables 1, 2) and
they also have well defined the biological pathways or gen-
ome, transcriptome and proteome underlining the change
of metabolites (Tables 3, 4). As a result, the new method-
ologies of metabolomics have provided invaluable tools for
the examination of these interactions on a global scale, and
offer an alternative means of investigation to that of some
of the more reductionist molecular biology approaches.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Metabolome 
• Low molecular weight:    
molecules (<10,000 Daltons)
• ~3,000 metabolites found
• Amino acid, carbohydrates, 
lipids, cofactors, nucleosides and 
other metabolites
• Small molecules, drugs and 
peptides
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Figure 1 The work flow of Mass Spectrometry Schematic (MS-S) for metabolome analysis. The left panel depicts a triple-collector system
arranged to analyze molecules and an example of total mass spectrum for the compounds A, B, C, D, E, F, and G in a reaction. The right panel
outlines the relationship between the genome, proteome, and metabolome, as well as the significances of metabolomics.
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the concentrations and fluxes of endogenous metabolites
include, but are not limited to, 1H and 13C nuclear
magnetic resonance (1H- and 13C-NMR) spectroscopy,
gas chromatography-mass spectrometry (GC-MS), gas
chromatography-flame ionization detection (GC-FID),
direct infusion-mass spectrometry (DI-MS), and liquid
chromatography-mass spectrometry (LC-MS). Figure 1
shows how metabolomic technology (MS) works and
separates the molecules based on their different masses
in a typical reaction (Figure 1). As an addition to other
metabolomic databases listed in the tables, the spectral
database includes almost all spectrometries applied in
the metabolomics research (Table 5). However, due to
the wide range of metabolites and the dynamic nature of
their concentrations within the cell, a complete analysis of
the metabolome has thus far eluded description even when
a range of analytical approaches have been employed [6].
In addition, metabolomics has been increasingly applied to
the biomarker discovery of cardiovascular diseases, dia-
betes, and early changes of metabolites in obesity through
metabolic profiling in patients with metabolic syndrome
[7-9], MS-based metabolic profiling of acylcarnitines
species in insulin resistance animal models [10], cellular
lipid signaling[11], as well as profiling amino acids andacylcarnitines in obesity individuals [12]. Although various
methodologies have been employed, two technologies have
prevailed as the core methodologies of metabolite profiling:
NMR [13] and MS, with the latter coupled to an array of
separation techniques including GC and LC.
The integration of metabolomics with genomics,
transcriptomics, and proteomics plays an important role
in the research of systems biology. In many cases mRNA
expression and protein levels are poorly correlated, and
in certain cases they may be even more poorly correlated
with phenotypes which are several steps “up-stream” of
the flow of genetic information. Besides, transcriptomics
studies can be the quite costly, in contrast, proteomic
studies are relatively time consuming. Meanwhile, the
application of metabolomics to a mouse model of disease
can rapidly profile a range of tissues. This profiling would
allow us to understand how one gene mutation affects
metabolism in the blood plasma and multiple tissues such
as white adipose tissue, fast- and slow- twitch skeletal
muscle, and cardiac tissue. As result, an in vivo model can
be built on systemic metabolism changes across the
organism following a genetic modification [14], not all of
those findings in transgenic models can be translated into
the human diseases yet. In particular, recent progress has
been made toward the understanding of the highlighted
Table 1 List of compound and disease/physiology databases
Link of the databases Teams or specificity Numbers of metabolites Data included
ChEBI (http://www.ebi.ac.UK/chebi/) Chemical Entities of Biological Interest;
Small chemical compounds
More than 15,500 chemical entities Structure and nomenclature information
ChemSpider (http://www.chemspider.com/) An aggregated database of organic molecules More than 20 million compounds Search utilities and a large number of
calculated physicochemical property values.
KEGG Glycan (http://www.genome.jp/kegg/glycan/) A collection of experimentally
determined glycan structures
More than 11,000 glycan structures from
a large number of eukaryotic and prokaryotic
Glycan structures
METAGENE (http://www.metagene.de/) A knowledgebase for inborn errors of metabolism 431 genetic diseases Information about the disease, genetic cause,
treatment and the characteristic metabolite
concentrations or clinical test used for the
diagnosis of disease
OMIM (http://www.ncbi.nlm.nih.gov/omim/) Online Mendelian Inheritance in Man:
a comprehensive compendium of
human genes and genetic phenotypes
Contain information on all known Mendelian
disorders and over 12,000 genes
The relationship between
phenotype and genotype
OMMBID (http://www.ommbid.com/) An web-accessible book/encyclopedia
describing the genetics, metabolism,
diagnosis and treatment of metabolic disorders
Hundreds of metabolic disorders Extensive reviews, detailed pathways, chemical
structures, physiological data and tables

















Table 2 List of drug metabolic databases
Link of the databases Teams or specificity Numbers of metabolites Data included
DrugBank (http://www.drugbank.ca/) A blended bioinformatics and cheminformatics
database of drugs and their targets
~4,800 drug entries (>1,350 FDA*1-approved
small molecule drugs, 123 biotech drugs,
71 nutraceuticals and >3,243 experimental drugs.
Chemical, pharmacological and
pharmaceutical data; sequence, structure,
and pathway information
PharrmGKB (http://www.pharmgkb.org/) A central repository for genetic, genomic,
molecular and cellular phenotype data
and clinical information of people who
have participated in pharmacogenomics
research study
>20,000 genes; Data of clinical and basic pharmacokinetic
and pharmacogenomic research in the
cardiovascular, pulmonary, cancer, pathways,




~470 genetic variants affecting drug metabolism
STITCH (http://stitch.embl.de/) Search tool for interactions of chemicals More than 68,000 different chemicals
including 2,200 drugs, and connects them
to 1.5 million genes across 373 genomes
Information about interaction of metabolic
pathways, crystal structures, binding
experiments and drug-target relationships
SuperTarget (http://insilico.charite.de/supertarget) A core dataset of drug-target relations ~7,300 relations to 1,500 drugs Drug-target relations; tools for 2D*2 drug
screening and sequence comparison of
the targets
Therapeutic Target DB (http://xin.cz3.nus.edu.sg/
group/ttd/ttd.asp)
A therapeutic target database 1,535 targets and 2,107 drugs/ligands Information about the known therapeutic
protein and nucleic acid targets; the targeted
disease conditions; the pathway information;
and drug/ligands of targets

















Table 3 List of metabolic pathway databases
Link of the databases Teams or specificity Numbers of metabolites Data included
BioCyc (http://humancyc.org/) Pathway/Genome database 371 pathways Tier 1: metabolites, enzymes activators/inhibitors
and cofactors; Tier 2 and Tier 3: computationally
predicted pathways and gene codes.
HumanCyc (http://biocyc.org/) Bioinformatics database 28,783 genes Metabolic pathways and the human genome
KEGG (http://www.genome.jp/kegg/) Kyoto Encyclopedia of Genes and Genomes 372 reference pathways, >15,000 compounds,
7,742 drugs and ~11,000 glycan structures
Metabolic pathways hyperlinked to metabolite
and protein/enzyme information
Metacyc (http://metacyc.org/) Data base of nonredundant, experimentally
elucidated metabolic pathways
More than 1,100 pathways of more than
1,500 different organisms
Pathways of both primary and secondary metabolisms
as well as associated compounds, enzymes, and genes
Reactome (http://www.reactome.org/) A curated, peer-reviewed knowledge
base of biological pathways
More than 2,700 proteins, 2,800
reactions and 860 pathways for humans

















Table 4 List of comprehensive metabolomic databases
Link of the databases Teams or specificity Numbers of metabolites Data included
BIGG (http://bigg.ucsd.edu) A metabolic reconstruction of human
metabolism
1,496 ORFs*1, 2,004 proteins, 2,766 metabolites, and
3,331 metabolic and transport reactions
Literature-based genome-scale
metabolic reconstruction
BinBase (http://bigg.ucsd.edu/) A GC-TOF*2 metabolomic database Unknown Metabolomic database
HMDB (http://www.hmdb.ca) Human Metabolome Database; More than 6,500; Chemical data; Clinical data; Molecular
Biology/Biochemistry dataLink to ~ 1,500 protein and DNA sequencesSmall molecule metabolites
SetupX (http://bigg.ucsd.edu/; http://fiehnlab.ucdavis.
edu:8080/m1/readme.jsp)
A web-based metabolomics LIMS*3 unknown Display of GC-MS*4 metabolomic data
SMPDB (http://www.smpdb.ca/) The small molecule pathway database More than 350 small molecule pathways Human metabolic pathways, metabolic
disease pathways, metabolite signaling
pathways and drug-action pathways
SYSTOMONAS (http://fiehnlab.ucdavis.edu:8080/m1/login.
jsp)
Systems biology of pseudomonas--systems
biology studies of Pseudomonas species.
Extensive Transcriptomics, proteomic, metabolomic
and metabolic reconstructions

















Table 5 List of spectral databases
Link of the databases Teams or specificity Numbers of metabolites Data included
BML-NMR (http://www.bml-nmr.org) The Birmingham Metabolite Library Nuclear
Magnetic Resonance (NMR) database
3,328 NMR*1 spectra of 208 common
metabolite standards.
2-D 1HJ*2 -resolved spectra and 1-D 1H spectra
BMRB (http://www.bmrb.wisc.edu/
metabolomics/)
The central repository for experimental NMR
spectral data, primarily for macromolecules
~500 molecules Structures, structure viewing applets, nomenclature data,
extensive 1D and 2D spectral peak lists, raw spectra and FIDs
Fiehn GC-MS Database (http://fiehnlab.
ucdavis.edu/Metabolite-Library-2007/)
The library contains data on compounds for
which GC/MS data have been collected
713 compounds Name, structure, CAS ID*3 of compounds; Spectra and
retention indices of GC/MS data
Golm Metabolome Database
(http://gmd.mpimp-golm.mpg.de/)
A public access to custom GC/MS libraries n/a Mass spectral and retention time index libraries
HMDB (http://www.hmdb.ca) Human Metabolome Database; More than 6,500; Chemical data; Clinical data; Molecular
Biology/Biochemistry dataLink to ~ 1,500 protein and DNA
sequences
Small molecule metabolites
Massbank (http://www.massbank.jp/) A mass spectral database of experimentally
acquired high resolution MS spectral of metabolites
>13,000 spectra from 1,900 different
compounds
Very detailed MS data and excellent
spectral/structure searching utilities
Metlin (http://metlin.scripps.edu/index.php) A repository for mass spectra metabolite data 15,000 structures including
more than 8,000 di and tripeptides
MS/MS, LC/MS *4 and FTMS*5 data
MMCD (http://mmcd.nmrfam.wisc.edu/) The Madison Metabolomics
Consortium Database (MMCD)
~10,000 metabolite entries; experimental
spectral data on ~500 compounds
Chemical formula, names and synonyms, structure,
physical and chemical properties; NMR and MS data of
compounds, NMR chemical shifts, etc.
Abbreviations: *1NMR: nuclear magnetic resonance; *2-D-HJ: 2 dimensional 1H- jump-and –return pulse spectrum; *3 CAS ID: compound ID assigned by chemical abstract service; *4 LC/MS: liquid chromatograph/mass
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this article, we focus to review the applications of
metabolomics, and the changes of metabolites as well as
the specific pathways underlining the pathophysiology in
atherosclerosis, metabolism syndrome, and obesity.
Applications of metabolomics in atherosclerosis
Metabolomics has being applied to analyze atheroscler-
otic samples for biomarker discovery and circulating
metabolite profiling that may play an important role as
regulatory signals in the development of the disease. In
order to identify differences in plasma metabolites of
individuals with and without ischemia, Sabatine et al.
[15] employed a MS-based technology in the study. The
results showed that lactic acid and its metabolites, such
as hypoxanthine, inosine, and alanine that are involve in
skeletal muscle AMP catabolism increase after exercise
stress test in both patients and healthy controls. In contrast,
there was significant discordant regulation of multiple
metabolites in patients with ischemia demonstrated by
increased MET193 and MET221 and decreased plasma
levels of γ-aminobutyric acid, MET288, oxaloacetate, citrul-
line, and argininosuccinate, which were caused by the pres-
ervation of citric acid cycle intermediates to defend ATP
production in the myocardium. This metabolomics study
exhibited a discovery of novel biomarkers of acute myocar-
dial ischemia. In addition, pattern-recognition techniques
were also applied to 1H-NMR spectra of human serum.
The study showed that the most influential factors for the
development of severe atherosclerosis are increased metab-
olites of CH2 chain (chemical shift ð1.26, ð1.3 and ð1.34 on
600 MHz 1HNMR spectra) and CH3 group (chemical shift
ð86) produced from fatty acid side chains in lipid, in
particular LDL and VLDL). In this study, investigators can
correctly diagnose not only the presence, but also the sever-
ity, of angiographically-defined coronary heart disease with
a specificity of >90% [16]. The similar serum metabolic pro-
files and chemical shift patterns were indicated in patients
with high systolic blood pressure (SBP), demonstrating that
there was a relationship between serum metabolic profiles
and blood pressure, which in part was thought due to lipo-
protein particle composition differences between the
samples [17]. Taken together, these studies showed for the
first time a technique capable of providing an accurate,
noninvasive, and rapid diagnosis of coronary heart disease
and hypertension, which can be used clinically either in
population screening or effective targeting of treatments.
However, some authors argued about the predictive power
and specificity of 1H-NMR methodology in the detection of
coronary artery disease (CAD), stating that the analysis was
dependent mainly on the major lipid regions of the spectra,
and that many variables, including gender and drug
treatment, affect lipid composition and are potential
confounders [18].Recently, investigators applied GC-MS fingerprinting to
the plasma samples of patients with acute coronary
syndrome in comparison with that of healthy controls for
disease diagnosis with pattern recognition techniques.
Interestingly, the results showed that acute coronary
syndrome (ACS patients had decreased plasma citric acid,
4-hydroxyproline (4OH-Pro), aspartic acid, and fructose;
and increased lactate, urea, glucose, and valine [19].
Though the clear cross-talk of those changes to ACS needs
to be further studied, the decrease in plasma 4OH-Pro was
especially interesting because circulating 4OH-Pro is
thought to prevent the binding of LDL to lipoprotein previ-
ously deposited in the vascular wall, as well as releasing
already-deposited LDL from therosclerotic lesions. Further-
more, 4OH-Pro is a component of collagen, which also
confers stability to the atherosclerotic plaque in the vessels.
In a similar study [20], the investigators applied both
GC-MS and 1H-NMR to investigate the plasma of patients
with stable carotid atherosclerosis in comparison to that of
healthy subjects. The results showed that these techniques
complement each other and enable a clearer picture of the
biological samples to be interpreted not only for classifica-
tion purposes, but also more importantly to define the
metabolic state of patients with carotid atherosclerosis. The
metabolomic profiles showed at least 24 metabolites that
were significantly modified in the group of atherosclerotic
patients by this “nontargeted” procedure. Those metabolites
include, but not exclusively, increased D-glucose, and
decreased D-fructose, pyruvate (pyr) and myoinositol (myo)
which are involved in impaired insulin sensitivity, glycolysis,
and glycogenogenesis; increased 3-OH—butyrate (3HB),
acetoacetate (AcAc), long chain-fatty acids (such as palmi-
tate, stearate, 11-transoctadecenoate, and linoleate),
D-glycerol (gol), and decreased medium-chain fatty
acids (hexanoate and laurate) produced from increased
lipolysis and decreased lipogenesis, β-oxidation of fatty
acids and deficient insulin signaling. In addition, increased
2-hydroxybutyrate was also found in this study, of which
the increase was believed due to decreased L-threonine.
Since most of the changes are associated to alterations of
the metabolism characteristics of insulin resistance, the
metabolic profiling in carotid atherosclerosis can be
strongly related to metabolic syndrome. In summary, these
studies highlight two important points. First, GC-MS and
1H NMR fingerprints can provide complementary informa-
tion in the identification of altered metabolic pathways in
patients with carotid atherosclerosis. Second, correlations
among results from both techniques, instead of a single
study, can provide a deep insight into the patient state.
A number of laboratories have applied metabolomics
to understand the progression of atherosclerosis in the
apolipoprotein E (ApoE)*3Leiden mouse or the athero-
genic ApoE gene knock-out (ApoE-/-) mouse model
[21,22]. In the ApoE3-Leiden (APO*E3) transgenic mice,
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lesions, there are significant increases in liver-type fatty
acid binding protein (L-FABP), in triglycerides, and se-
lected bioactive lysophosphatidylcholine compared to con-
trols, indicating a rapid identification of early protein and
metabolite markers of disease pathology of this model. A
correlation analysis of identified genes, proteins, and lipids
was used to construct an interaction network, though
some identified changes needed to be “translated” into hu-
man disease. Taken together, these results indicate that in-
tegrative biology is a powerful tool for rapid identification
of early markers and key components of pathophysio-
logical processes, and constitute the first application of
this approach to a mammalian system [21]. Furthermore,
the metabolic profiles fulfilled with LC-MS/MS also
revealed that 1-Cys peroxiredoxin (1-cyc prx), a novel anti-
oxidant conferring protection against oxidative membrane
damage, was predominantly present as reduced protein in
apolipoprotein E+/+ vessels but is oxidized in apolipopro-
tein E-/- vessels[22], indicating that increased oxidative
stress plays an important role in the development of
atherosclerosis in this model. To identify the changes of
protein and metabolite in the vessels of ApoE-/- mice on
normal chow diet using proteomic and metabolomic tech-
nologies [22], investigators analyzed and mapped the pro-
tein expression in aortic smooth muscle cell (SMC)s of
mice using two-dimensional gel electrophoresis (2-DE),
matrix-assisted laser desorption-ionization time-of-flight
mass spectrometry (MALDI-TOF MS) and LC-MS/MS
[23]. In this study, 79 protein species were identified, of
which the expression levels were increased during various
stages of atherogenesis. Immunoglobulin deposition, redox
imbalance, and impaired energy metabolism were found to
precede lesion formation in ApoE-/- mice. Meanwhile,
NMR revealed a decline in alanine and a depletion of the
adenosine nucleotide pool in vessels of 10-week-old
ApoE-/- mice. Furthermore, attenuation of lesion formation
was associated with alterations of NADPH generating malic
enzyme, which provides reducing equivalents for lipid
synthesis and glutathione recycling, and successful replen-
ishment of the vascular energy pool [23]. Given that
increased dietary cholesterol is associated with atherogen-
esis in man and mouse, in a combined transcriptomics and
metabolomic study, investigators [24] used novel whole-
genome and HPLC/MS-based metabolome technologies to
investigate the proinflammatory components of athero-
sclerosis that originate in livers of the groups of
ApoE*3Leiden mice fed with cholesterol-free (control), low
cholesterol (LC; 0.25%), and high cholesterol (HC; 1%)
diets. The results showed that induced atherosclerosis was
proportional to dietary intake of cholesterol because HC
stress significantly activated specific proinflammatory path-
ways that is the platelet-derived growth factor (PDGF),
interferon-γ (IFNγ), interleukin-1 (IL-1) and tumor necrosisfactor-α (TNF-α) signaling pathways. Activation of these
proinflammatory pathways with HC treatment leads to a
significant up-regulation of regulators, such as mitogen-
activated protein kinases (MAP kinases), complement
factors, and acute phase proteins such as serum amyloid A
(SAA). Notably, several of these regulators control both
lipid metabolism and inflammation, which suggests that
the high-cholesterol diet not only induces inflammation
but also alters lipid metabolism, thereby linking the
dyslipidemia and inflammation with the early lesion
formation of atherogenesis with this animal model
Apparently, the study demonstrated that the combination
of transcriptomics and metabolomics is a newly developed,
functional systems biology tool, which allows for better def-
inition of the perturbations associated with a given dietary
intervention and to identify the novel regulatory pathways
and transcriptional regulators controlling both lipid
metabolism and inflammatory responses.
The usefulness of metabolomics in pathology investi-
gation was further cemented, in which NMR-based
metabolomics of mouse urine was used in conjunction with
the traditional staining and imaging of aortas for the
characterization of disease advancement, that is, plaque
formation in untreated and angiotensin I-converting
enzyme inhibitor Captopril-treated apoE-/- mice [25]. The
result showed that xanthine and ascorbate were elevated in
the untreated mice. The increased xanthine level in the
untreated group was thought as a marker for the plaque
formation in apoE-/- mice. Meanwhile, the elevated ascor-
bate in the untreated group is consistent with findings that
stress will cause more ascorbate to be produced, be it to
counter greater ROS or for vasodilation. Interestingly, the
metabolomics approach with multivariate analysis was able
to differentiate the Captopril-treated from the untreated
mice in general agreement with the staining results. Metab-
olites were identified to be indicative of disease progression
because of their role in oxidative stress. Plasma and urine
samples from atherosclerotic and control rats have been
compared by ultra-fast liquid chromatography coupled
to ion trap-time of flight (IT-TOF) mass spectrometry
(UFLC/MS-IT-TOF) and 12 metabolites in rat plasma
and 8 metabolites in urine were identified as potential
biomarkers. Concentrations of leucine, phenylalanine, tryp-
tophan, acetylcarnitine, butyrylcarnitine, propionylcarnitine,
and spermine in plasma and 3-O-methyl-dopa, ethyl
N2-acetyl-L-argininate, leucylproline, glucuronate, t6A
N6-(N-threonylcarbonyl)-adenosine and methyl-hippuric
acid in urine decreased in atherosclerotic rats. Meanwhile,
ursodeoxycholic acid, chenodeoxycholic acid, lyso-phospha-
tidylcholines (lysoPC) C16:0, lysoPC C18:0 and lysoPC
C18:1 in plasma and hippuric acid in urine were in higher
levels in atherosclerotic rats. The altered metabolites dem-
onstrated abnormal metabolism of phenylalanine,
tryptophan, bile acids and amino acids. This report
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disease research [26].
Applications of metabolomics in diabetes and obesity
The development of T2DM and obesity are highly corre-
lated with uptake of the high fat diet. These disorders
result in a number of metabolic perturbations including
imbalance of glucose metabolism and dyslipidemia in
key organs and blood plasma. These alterations lead to
changes in the proportions of very low density lipopro-
tein (VLDL)/low density lipoprotein (LDL) to high dens-
ity lipoprotein (HDL) and induce atherosclerosis. The
disorders interact to produce what has been referred to
as a Metabolic Syndrome whereby a number of separate
risk factors for atherosclerosis interact to greatly magnify
the risk of developing cardiovascular disease. Thus,
metabolic changes are central to these disorders, and we
would expect that any process aimed at measuring
global metabolism changes would provide a good
description of the phenotype of these diseases. There-
fore, metabolomics has been used to identify the poten-
tial new disease markers of diabetes and obesity. In one
study, LC-MS followed by multivariate statistical analysis
was successfully applied to the metabolic profiling of
plasma phospholipids in T2DM. The specific phospholipid
molecular species, such as glycerophosphophoethanolamine
(GPE), diacyl phophatidylethanolamine, and lyso-phosphati-
dylcholines (Lyso-PC C16:0 and C18:0), detected at m/z
range from 480 to 788 on LC-MS were identified as poten-
tial biomarkers for classifying the DM2 patients from the
controls. With this methodology, it was possible not only to
differentiate the T2DM from the controls but also to identify
the potential biomarkers with LC-MS/MS. The proposed
method shows that LC-MS combined with multivariate stat-
istical analysis is a complement or an alternative to NMR
for metabolomics applications [7]. In the Insulin Resistance
Atherosclerosis Study (IRAS), in which lipoprotein particles
were measured using NMR, the investigator showed that a
range of lipoprotein abnormalities in prediabetic individuals,
including compositional changes in HDL (decreased) and
VLDL (increased). These findings extend previous work
indicating a proatherogenic state in healthy, nondiabetic
subjects who subsequently develop diabetes [8], revealing
that declines in glycerol and leucine/isoleucine (markers of
lipolysis and proteolysis, respectively) jointly provide a
predictor of insulin sensitivity [27,28]. In a clinical study
with type 1 diabetic (T1D) humans, MS revealed significant
perturbations in the levels of plasma amino acids and
amino acid metabolites during insulin deprivation as well
as several metabolic pathways like protein synthesis and
breakdown, gluconeogenesis, ketogenesis, amino acid
oxidation, mitochondrial bioenergetics, and oxidative
stress are also perturbed [29]. An ultra-performance
LC quadruple–time of flight mass spectrometry(UPLC-q-TOF-MS)-driven non-targeted metabonomics
study showed considerable changes of metabolite
fingerprints in pre-diabetes, including increases in fatty
acid- (FFAs C18:2, C16:1, C20:4 and C22:4; saturated FFA
palmitate and FFA stearate, unsaturated FFA Oleate) and in
glycochenodeoxycholic acid; and decrease in Lyso-PC-
metabolism, uric acid, as well as tricarboxylic acid
cycle -metabolism (TCA cycle) [30]. In another clinical
study using targeted LC-MS profiling of blood plasma,
investigators aimed to investigate whether metabolite pro-
files could predict the development of diabetes. The results
showed a highly significant association between the levels
of five branched chain and aromatic amino acids isoleucine,
leucine, valine, tyrosine, and phenylalanine and the prob-
ability of future onset of diabetes. A combination of three
amino acids predicted future diabetes (with a more than
fivefold higher risk for individuals in top quartile). The
results were later replicated in an independent, prospective
cohort. These findings underscore the key role of amino
acid metabolism early in the pathogenesis of diabetes and
suggest that amino acid profiles could aid in diabetes risk
assessment [31]. Furthermore, examination of plasma
esterified fatty acids (EFAs) and non-esterified fatty acids
(NEFAs) metabolic profiling using GC-MS indicated that
most of the arachidonic acids (the class of C20 FAs) had
significantly distinguishing characteristics in pathological
progression. Most likely, because arachidonic acids are
involved in in the anabolism of prostaglandins, these mole-
cules are important modulators of inflammatory processes.
Besides, most of the plasma EFA concentrations were
reduced in DM cases when compared with control group,
while NEFAs increased significantly. The EFA level fluctu-
ation was suspected to be related with the cellular self-
repair mechanism and NEFA variation resulting from EFAs
self-adjusting mechanism. These findings could indicate
potential biomarkers for monitoring the progression of DM
as well as diabetic nephropathy (DN) [32].
This targeted approach using gas-chromatography-mass
spectrometry has also been applied to insulin resistance
studies in vivo and an increase in phenylalanine metabo-
lites was in agreement with the known regulation of
the phenylalanine hydroxylase gene by Hnf1α[33].
MS-based metabolic profiling of acylcarnitines species
identified an increase in the concentration of lipid-derived
β-hydroxybutyrate in muscle of mice that overexpress hep-
atic malonyl-CoA decarboxylase and exhibit improved in-
sulin resistance [10]. Meanwhile, in wild-type mice fed
with a high-fat diet, significant changes to metabolites
in the liver were identified [34], including increases in
urea cycle intermediates, consistent with increased
deamination of amino acids used for gluconeogenesis,
and 1,5-anhydroglucitol, a previously identified marker of
short-term glycemic control. Of the identifiable metabo-
lites in plasma, wild-type mice fed with the high-fat diet
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related metabolites. These changes are consistent with
increased deamination of amino acids used for gluconeo-
genesis [34]. The findings are also supported by a study in
T2D rats and streptozotocin-induced diabetic rats (a type
I diabetes model) [35,36]. The metabolic effect of the
PPARγ activation and PPARδ activation in regulating
metabolism in adipose tissue and insulin sensitivity was
well-defined in vivo in white adipose tissue from ob/ob
mice (mice homozygous for the obese spontaneous muta-
tion of leptin gene) and in vitro in cultured 3T3-L1 adipo-
cytes using 1H NMR and MS metabolomics. The metabolic
effects of the receptors were readily distinguished, with
PPARγ activation characterized by increased fat storage,
synthesis and elongation, while PPARδ activation caused
increased fatty acid β-oxidation, tricarboxylic acid cycle rate
and oxidation of extracellular branch chain amino acids.
Stimulated glycolysis and increased fatty acid desaturation
were common pathways for the agonists. PPARγ and
PPARδ restore insulin sensitivity through varying mecha-
nisms. PPARδ activation increases total oxidative metabol-
ism in white adipose tissue, a tissue not traditionally
thought of as oxidative. However, the increased metabolism
of branch chain amino acids may provide a mechanism for
muscle atrophy, which has been linked to activation of this
nuclear receptor. PPARδ has a role as an anti-obesity target
and as an anti-diabetic target, and hence may target both
the cause and consequences of dyslipidemia [9]. These
results were supported by a recent review that defined the
role PPARδ in regulating fatty-acid oxidation in adipose
tissue and the interaction between aging and PPARα in liver
[37]. Obese individuals with or without T2D are charac-
terized by dysregulated fatty acid and amino acid metabol-
ism. Recent investigations have applied comprehensive
metabolomics profiling to gain a broad understanding of
the metabolic differences between lean, obese, and diabetic
individuals. An investigator demonstrated, using targeted
metabolomics, elevations in acylcarnitines (AcyCN) and
amino acid concentrations; in particular branched chain
amino acids and C3, C5, C6, and C8:1 acylcarnitines [12].
Furthermore, overweight/obese men showed a higher pro-
portion of stearic acid and lower proportion of oleic acid in
serum phospholipids. Additionally, overweight/obese indi-
viduals had higher fat intake and lower ratios of polyunsat-
urated fatty acids to saturated fatty acids when compared
to healthy controls. Three lysoPCs were identified as poten-
tial plasma markers and the study confirmed eight known
metabolites for overweight/obesity men as overweight/
obese subjects showed higher levels of lysoPC C14:0 and
lysoPC C18:0 and lower levels of lysoPC C18:1 than lean
subjects. The result indicates an abnormal metabolism of
two branched-chain amino acids (BCAA), two aromatic
amino acids, and fatty acid synthesis and oxidation [38,39].
Recent studies have associated the compromised insulinsignaling in patients with obesity, prediabetes, and T2DM
with altered intermediary metabolism of fats and amino
acids. The increase in blood concentrations of selected es-
sential amino acids and their derivatives, in particular,
BCAA, and/or carnitine esters derived from partial BCAA
catabolism, sulfur amino acids, tyrosine, and phenylalanine,
are apparent with obesity and insulin resistance, often
before the onset of clinically diagnosed T2DM [40]. The
decreases in the metabolism of essential fatty acids and
polyunsaturated fatty acids including eicosapentaenoic acid
(EPA), docosahexaenoic acid (DHA), and arachidonic acid
(AA) are believed to play a significant role in the patho-
physiology of metabolic syndrome and diabetes mellitus
[41]. A targeted metabolomic investigation of the plasma
pattern of families burdened with early onset cardiovascular
disease revealed decreased linoleic acid (LA) and AA as
biomarkers [42] because the adequate amounts of EPA,
DHA, LA, and AA synthesized and released by ECs can
prevent aggregation of platelets on their surface and
decrease the expression of adhesion molecules and produc-
tion of pro-inflammatory cytokines, such as IL-1β, IL-2,IL-
6 and TNF-α, so that atherosclerosis would not occur. Of
note, bile acids (BAs) are now discussed as metabolic inte-
grators of whole-body energy homeostasis. In fact, they
were among the metabolites showing the most striking
change during oral glucose tolerance test (OGTT) in a
targeted metabolic profiling approach [27] and in a non-
targeted metabolomics study [43] though their characteris-
tic biphasic alterations (increase-decrease-increase pattern)
during OGTT needs to be better understood. Also pertin-
ent, BAs can influence glucose and lipid metabolism [44]
through the activation of farnesoid X receptor (FXR), a
member of the superfamily of ligand-activated nuclear
receptor transcription factors, lowers plasma triglyceride
synthesis by a mechanism that may involve the repression
of hepatic sterol regulatory element-binding protein
(SREBP)-1c expression and/or the modulation of glucose-
induced lipogenic genes. FXR-/- mice display both impaired
glucose tolerance and decreased insulin sensitivity, there-
fore, the findings suggest that FXR activity can be a poten-
tial biomarker of the development and treatment of
metabolic syndrome and T2D.
Potential mechanisms and the signaling pathways
underlying the metabolite profiling changes associated
with atherosclerosis, diabetes, and obesity
The mechanisms associated with accelerated atheroscler-
osis development seen with the insulin resistance-
associated conditions like T2DM and obesity are still under
investigation, but it is believed that a decline in the bioavail-
ability of nitric oxide (NO) and an increase in reactive
oxygen species (ROS) are the most crucial factors. NO has
the functions of vasorelaxant [45], anti-inflammatory [46],
antiproliferative [47], antioxidant [48], and antiplatelet
Table 6 Summary of identified metabolites in atherosclerosis
Metabolites Change Sources or pathways Species of study PMID
MET193 , MET221 Metabolites of CH2 chain
and CH3 chain fatty acids





glucose, lactate, urea and valine ↑ Carbohydrate and amino acid metabolism human plasma 20425260,
19813770
3-OH-butyrate, acetoacetate, palmitate, stearate, 11-transoctadecenoate,
linoleate, and D-glycerol
↑ Increased lipolysis and decreased lipogenesis, β-oxidation
and deficient insulin signaling
human plasma 19813770
2-hydroxybutyrate ↑ Decreased L-threonine human plasma 19813770
Oxidized 1-Cys- peroxiredoxin ↑ Increased oxidative stress ApoE -/- mouse and mouse
aortic sooth muscle cells
16123314
γ-aminobutyric acid, MET288, citrulline, argininosuccinate, oxaloacetate ↓ Preservation of citric acid metabolism intermediates human-plasma 16344383
4-hydroxyproline (4OH-Pro), citric acid, aspartic acid, fructose, ↓ Amino acid and carbohydrate metabolism, deficient
protection of 4OH-pro in vascular wall
human plasma 19813770
20425260
D-fructose, pyruvate, myoinostol , medium-chain
fatty acids (hexanoate and laurate)
↓ Impaired insulin sensitivity, glycolysis and glycogenogenesis;
increased lipolysis and decreased lipogenesis
human plasma 19813770
reduced 1-Cys peroxiredoxin, alanine, and NADPH generating
malic enzyme
↓ Increased oxidative stress Reduced equivalents
for lipid synthesis and glutathione recycling
ApoE -/- mouse and mouse
aortic smooth muscle cells
16123314
16240290
Cholesterol, LDL and VLDL ↑ Activated inflammatory pathways, then upregulation of





Xanthine, ascorbate ↑ Plaque formation of vessels Stress induced
more ascorbate production and oxidative stress
ApoE -/- mouse urine 19565469
Ursodeoxycholic acid, chenodeoxycholic acid, lysoPC
(C16:0, C18:0, C18:1)
↑ Abnormal metabolism of bile acids and amino acids atherosclerosis rat plasma 19576453
Hippuric acid ↑ Abnormal metabolism of bile acids and amino acids atherosclerosis rat urine 19576453




Leucine, phenylalanine, tryptophan, acetylcarnitine, butyrylcarnitine,
propionylcarnitine, spermine
↓ Abnormal metabolism of amino acids Atherosclerotic rat plasma 19576453
3-O-Methyl-dopa, ethyl N2-acetyl-L-argininate, leucylproline, glucuronate,
N6-threonylcarbonyl-adenosin and methyl-hippuric acid
↓ Abnormal metabolism of amino acids,
phenylalanine, tryptophan and bile acids
atherosclerosis rat urine 19576453

















Table 7 Summary of identified metabolites in diabetes or obesity
Metabolites Change Sources or pathway Species of study PMID
Glyceriphophphoetanolami-ne,
diacyl-phophatidylethanolamine
↑ Impaired phospholipid metabolism diabetic patient plasma 15987116
Lyso-PCs* ↑ Lipid metabolism diabetic patient plasma 15987116
VLDL* ↑ Lipoprotein abnormalities Pre-diabetic patient plasma 15983261
Fatty acids (C18:2, C16:1, C20:4 and C22:4);
saturated free fatty acid palmitate
and stearate,; unsaturated Oleate-.
↑ Decreased metabolism of LysoPC*,
uric acid and tricarboxylic acid cycle
Pre-diabetic patient plasma 20676218
Arachidonic acids, non-esterified fatty acids ↑ Anabolism of prostaglandins
Modulators of inflammatory processes
diabetic patient plasma 21338761
isoleucine, leucine, valine, tyrosine,
and phenylalanine
↑ Abnormal metabolism of branched




HDL* ↓ Lipoprotein abnormalities Pre-diabetic patient plasma 15983261
Glycerol, leucine/isoleucine ↓ Lipolysis and proteolysis, Pre-diabetic patient plasma 18682704,
20976215
Esterified fatty acids ↓ Cellular self-repair mechanism diabetic patient plasma 21338761
phenylalanine ↑ Impaired regulation of the
phenylalanine hydroxylase
gene by Hnf1α gene
Insulin resistance patient, Type 2
diabetes mellitus mouse (Hnf1α-null





C3, C5, C6, and C8:1 acylcarnitines ↑ Increased catabolism of a
branched-chain amino acid
Obesity patients serum 19356713
Stearic acid ↑ Change of serum phospholipid
contents
Obesity patients serum 20560578
LysoPC* (C14:0, C18:0) ↑ Abnormal metabolism of BCAA*,




Sulfur amino acids, tyrosine ↑ Partial BCAA catabolism Metabolic syndrome patient 19357637
Farnesoid X receptor ↑ Superfamily of ligand-activated nuclear
receptor transcription factors
Impaired glucose tolerance
and insulin resistance patient
19126757
Oleic acid ↓ Change of serum phospholipid contents Obesity patients serum 20560578
LysoPC* (C18:1) ↓ Abnormal metabolism of BCAA*,




Eicosapentaenoic acid, docosahexaenoic acid,
arachidonic acid
↓ Metabolism of essential fatty acids
and polyunsaturated fatty acids
Patient of metabolic syndrome
and diabetes mellitus
16892270
↑: Increased; ↓: Decreased.
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http://www.biomarkerres.org/content/1/1/17actions [49], demonstrating a crucial role in preventing
endothelial dysfunction. The decline in the bioavailability of
NO occurs as a result of reduced biosynthesis of NO and/
or increased degradation by ROS. Several pieces of evidence
have shown that impaired NO-dependent vasodilatation
can predict future cardiac events and the development of
coronary artery disease [50,51]. A range of studies have pro-
vided compelling evidence supporting a strong association
between obesity, insulin resistance, and NO bioavailability
[52-59]. Furthermore, in a diet-induced model of obesity
the data has shown that insulin-mediated NO release is
blunted in the early development of obesity [60], which is
believed to be associated with increased endothelial cell-
derived ROS. This finding was supported by a study in a
non-obese model of whole body insulin resistance, where
reduced basal and insulin-mediated NO release was
demonstrated [61], as a result of increased endothelial cellnicotinamide adenine dinucleotide phosphate (NADPH)
oxidase-derived ROS from vascular oxidative stress [62].
Oxidative stress is thought to play a pivotal role in the
pathophysiology of atherosclerosis [63], and insulin resist-
ance [64]. A prevailing theory is that increased delivery of
lipids to muscle tissues saturates the capacity for mitochon-
drial ß-oxidation, leading to accumulation of bioactive
lipid-derived metabolites such as diacylglycerols and
ceramides in the extra mitochondrial space and the activa-
tion of stress/serine kinases that interfere with insulin
action. More recent studies have shown that fatty acid oxi-
dation is actually increased in muscle tissues in response to
high-fat feeding, but with no corresponding increase in
TCA cycle activity. This results in accumulation of incom-
pletely oxidized lipids in the mitochondria and depletion of
TCA cycle intermediates, possibly resulting in mitochon-
drial stress and interference with insulin actions [65].
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Figure 2 Metabolome analysis related to hyperglycemia/insulin resistance, obesity, and hyperlipidemia which contribute to the
development of endothelial dysfunction. The reciprocal effects of hyperglycemia/insulin resistance, obesity, and dyslipidemia result in
mitochondria stress/dysfunction via a complex of factors including oxidative stress, inflammation, incomplete fat oxidation, etc. As a result,
mitochondria dysfunction increases the production of reactive oxygen species (ROS) and decreases nitric oxide (NO), which ultimately produces
endothelial dysfunction and progressively causes atherosclerosis in macrovessels and microangiopathy in microvessels.
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number of different mechanisms including enhanced oxida-
tion of lipoproteins, activation of pro-inflammatory genes,
alteration of vascular smooth muscle cell phenotype, and
possibly most importantly, reduction of NO bioavailability.
ROS in the arterial wall are generated by several enzymes
including NADPH oxidase [66], xanthine dehydrogenase;
cytochrome p450 based enzymes, the mitochondrial elec-
tron transfer chain, as well as infiltrating inflammatory cells
[66]. Moreover, NADPH oxidase-derived ROS can impact
the major cellular sources of ROS, the mitochondria, to en-
hance superoxide production from this organelle [67]. As a
result of this complex interplay between sources of ROS, a
self-propagating cycle can ensue, amplifying endothelial
ROS production, reducing NO bioavailability and generat-
ing an increasingly proatherosclerotic environment. As
discussed above, mitochondrial electron transport is one of
the major producers of ROS. It was believed that uncoup-
ling protein 1 (UCP-1) in vascular smooth muscle cells
plays an important role in ROS production and atheroscler-
osis. The study in Semenkovich’s laboratory demonstrated
that UCP-1 generated ROS from vascular smooth muscle
cells leads to elevated ROS, reduced NO bioavailability and
accelerated atherosclerosis in mice on an ApoE deficient
background [68]. In contrast, overexpression of UCP-1 in
the endothelium was shown to blunt free fatty acid (FFAs)-
induced ROS production, suggesting that overexpression of
UCP-1 in the endothelium may protect against endothe-
lium cell dysfunction. The controversy warrants future
studies. In addition to vascular smooth muscle cells, the
role of mitochondrial dysfunction and ROS production in
the endothelium during diabetic and obesity states has been
extensively examined. It is believed that free fatty acids at
pathophysiological concentrations increases ROS produc-
tion in macrovascular endothelial cells through increasedexpression of NADPH oxidase-p47 (phox) and endothelial
oxidative stress, with selective compensatory upregulation
of antioxidant enzymes and Ser1177-phosphorylated
endothelial nitric oxide synthase (eNOS) [69]. Consistent
with findings in humans, NADPH oxidase has been
shown to be a key sources of ROS in adipose tissue of
obese mice [70]. Of note, endothelial cell NADPH oxidase
is thought to be the principal source of reduced NO
bioavailability and significant vascular oxidative stress in
insulin resistance [62,71].
Recently, NADPH oxidase has emerged as a major
source of superoxide in obese humans [72], those with
metabolic syndrome [73], patients with T2D [74], and
those with chronic heart failure [75]. Endothelin-1 and
nuclear factor-kappaB protein expression also appear
to be elevated in obese adults, suggesting a novel
insight into the molecular mechanisms linking obesity
to increased risk of clinical atherosclerotic diseases in
humans [69].
It is well established that obesity and T2DM are associ-
ated with proatherogenic dyslipidemia, which is character-
ized as an increase in plasma triglycerides and FFAs, a
reduction in HDL, and the presence of small, susceptible
LDL particles. A significant event in the early progression
of atherosclerosis is the permeation of small LDL particles
across the endothelial barrier and its subsequent accumula-
tion in the vascular wall [76]. The discrete steps in triglycer-
ide and FFAs handling increases ROS production and
activates NADPH oxidase and mitochondrial electron chain
to generate superoxide. The excessive ROS production
from one source can lead to enhanced production of ROS
from another. Phospholipids contained within LDLs are
highly susceptible to oxidation by ROS leading to the gener-
ation of oxidized phospholipids (OxPLs). OxPLs formation
triggers endothelial cell activation, facilitating monocyte
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kines [77]. Aside from this, elevated FFA itself may also
have direct effects on NO biosynthesis [78-80] and impair
mitochondrial uncoupling [81]. In insulin-resistant murine
models, FFA-induced ROS production substantially
inhibited prostacyclin synthase and eNOS activity in aorta
[69]. The interlocking effects of FFA on insulin resistance
and ROS may lead to a vicious cycle of lipotoxicity-induced
vascular dysfunction. Activation of the transcription factor
NF-kB signaling pathway and inflammatory mediator toll-
like receptor-4 (TLR4) signaling via the serine kinase inhibi-
tor kappaB kinase B (IKKB) activation may disrupt insulin
signaling via inhibition of insulin receptor substrate 1, Akt
(protein kinase B), and eNOS phosphorylation. In turn, this
leads to a decrease in NO production, perhaps instigating
inflammation and endothelial dysfunction [82-84].
Conclusions
In summary, as a research tool, metabolomics has been
successfully applied to the research of disorders such as
atherosclerosis, diabetes, and obesity. This technology
has been applied to the identification of novel bio-
markers not only for the diagnosis of diseases, but also
for the assessment of severity and provision of prognos-
tic information in these conditions. An emerging set of
metabolomics tools like MS, NMR, and other technolo-
gies enable the monitoring of metabolite profiles from
biological samples of these disorders that has provided
certain advantages relative to other “omics” technologies
like genomics, transcriptomics, and proteomics. Since it
measures chemical phenotypes that are the net result of
genomic, transcriptomics, and proteomic variability,
metabolomics provides the most integrated profile of
biological status. However, metabolomics is still a field
in its infancy, with some limitations and difficulties and
even confusions in the interpretation of its data. In con-
trast, Genome-wide association studies and mRNA pro-
filing by microarray analysis are relatively mature
technologies. Though metabolomics technologies are
still under development, they complement other func-
tional “omics” approaches, such as high throughput
genome sequencing, RNA expression analysis, and pro-
teomics. Metabolomics promises to be invaluable in
illuminating systems biology, the discovery of bio-
markers for disease diagnosis, and treatment assessment.
Metabolomic studies to date have identified quite diver-
sified metabolites in blood, tissues, and urine in the
process of atherosclerosis, diabetes, and obesity, of
which most are the intermediates of specific lipid clas-
ses, fatty acids, carbohydrates, amino acids, bile acids,
purine, pyrimidine, and proteins. The identified metabo-
lites and their sources and/or related mechanisms with
atherosclerosis, diabetes and obesity are summarized in
Tables 6 and 7. Accumulations of the metabolomicdatasets in these studies led us to the mechanism that
decreased NO bioavailability, increased ROS production
and mitochondria dysfunctions play crucial roles in the
production of metabolites associated with these disor-
ders (Figure 2). These findings may narrow the focus
of future metabolomic studies in understanding the
mechanisms of atherosclerosis, diabetes, and obesity.
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